PORTFOLIO

Projektdarstellungen auf der Webseite

Jedes von der Gebert Rüf Stiftung geförderte Projekt wird mit einer Webdarstellung zugänglich gemacht, die über die Kerndaten des Projektes informiert. Mit dieser öffentlichen Darstellung publiziert die Stiftung die erzielten Förderresultate und leistet einen Beitrag zur Kommunikation von Wissenschaft in die Gesellschaft.

Close

Hemetron – Better rapid tests for better health

Redaktion

The project management is responsible for the content of the information provided.

Projektdaten

  • Projekt-Nr: GRS-009/22 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 05.05.2022 
  • Dauer: 01.2023 - 06.2024 
  • Handlungsfeld:  InnoBooster, seit 2018

Projektleitung

Projektbeschreibung

Chronic inflammation is one of the largest unsolved healthcare issues of our society. Lifestyle adjustments such as optimized diets or increased physical activity are effective to fight chronic inflammations. However, every individual requires a different set of personalized adjustments. Unfortunately, there is currently no way to tailor the optimal anti-inflammatory measures to the personal needs of chronically inflamed individuals.
Hemetron develops a uniquely accurate and quantitative blood test for inflammation self-monitoring. Our solution empowers users to determine how to effectively decrease their inflammation.

Stand/Resultate

During our GRS InnoBooster project, we will improve our hand-held blood test prototype. It is important to bring a device to the market that provides optimal performance while also being easy to use. The project enables us to tailor our solution to the customers’ needs and accelerate our market entry.

Links

Am Projekt beteiligte Personen

E-mail for all requests webinfo@hemetron.notexisting@nodomain.comcom
Alexander Tanno, Postdoc at ETH Zürich and co-founder Hemetron AG
Yves Blickenstorfer, PhD at ETH Zürich and co-founder Hemetron AG
Vlastimil Jirasko, Postdoc at ETH Zürich and co-founder Hemetron AG

Letzte Aktualisierung dieser Projektdarstellung  05.03.2024